Nevertheless, one study unexpectedly showed that, although treatment with human monoclonal anti–CCL2/MCP-1 antibody was well tolerated by RA patients, there were no favorable immunohistologic or clinical effects [21]. The gene discussed is CCL2; the disease is rheumatoid arthritis.